Angiotensin-converting enzyme-1 gene insertion/deletion polymorphism may be associated with COVID-19 clinical severity: a prospective cohort study.
Journal
Annals of Saudi medicine
ISSN: 0975-4466
Titre abrégé: Ann Saudi Med
Pays: Saudi Arabia
ID NLM: 8507355
Informations de publication
Date de publication:
Historique:
entrez:
4
6
2021
pubmed:
5
6
2021
medline:
12
6
2021
Statut:
ppublish
Résumé
Angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism may play a role in the pathogenesis of coronavirus-19 disease (COVID-19). Investigate the relationship between ACE I/D polymorphism and the clinical severity of COVID-19. Prospective cohort study. Tertiary care hospital. The study included COVID-19 patients with asymptomatic, mild, and severe disease with clinical data and whole blood samples collected from 1 April 2020 to 1 July 2020. ACE I/D genotypes were determined by polymerase chain reaction and agarose gel electrophoresis. ACE DD, DI and II genotypes frequencies. 90 cases, 30 in each disease severity group. Age and the frequency of general comorbidity increased significantly from the asymptomatic disease group to the severe disease group. Advanced age, diabetes mellitus and presence of ischemic heart disease were independent risk factors for severe COVID-19 [OR and 95 % CI: 1.052 (1.021-1.083), 5.204 (1.006-26.892) and 5.922 (1.109-31.633), respectively]. The ACE II genotype was the dominant genotype (50%) in asymptomatic patients, while the DD genotype was the dominant genotype (63.3 %) in severe disease. The ACE II geno-type was protective against severe COVID-19 [OR and 95% CI: .323 (.112-.929)]. All nine patients (8.9%) who died had severe disease. The clinical severity of COVID-19 infection may be associated with the ACE I/D polymorphism. Small sample size and single center. None.
Sections du résumé
BACKGROUND
BACKGROUND
Angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism may play a role in the pathogenesis of coronavirus-19 disease (COVID-19).
OBJECTIVES
OBJECTIVE
Investigate the relationship between ACE I/D polymorphism and the clinical severity of COVID-19.
DESIGN
METHODS
Prospective cohort study.
SETTING
METHODS
Tertiary care hospital.
PATIENTS AND METHODS
METHODS
The study included COVID-19 patients with asymptomatic, mild, and severe disease with clinical data and whole blood samples collected from 1 April 2020 to 1 July 2020. ACE I/D genotypes were determined by polymerase chain reaction and agarose gel electrophoresis.
MAIN OUTCOME MEASURE
METHODS
ACE DD, DI and II genotypes frequencies.
SAMPLE SIZE
METHODS
90 cases, 30 in each disease severity group.
RESULTS
RESULTS
Age and the frequency of general comorbidity increased significantly from the asymptomatic disease group to the severe disease group. Advanced age, diabetes mellitus and presence of ischemic heart disease were independent risk factors for severe COVID-19 [OR and 95 % CI: 1.052 (1.021-1.083), 5.204 (1.006-26.892) and 5.922 (1.109-31.633), respectively]. The ACE II genotype was the dominant genotype (50%) in asymptomatic patients, while the DD genotype was the dominant genotype (63.3 %) in severe disease. The ACE II geno-type was protective against severe COVID-19 [OR and 95% CI: .323 (.112-.929)]. All nine patients (8.9%) who died had severe disease.
CONCLUSIONS
CONCLUSIONS
The clinical severity of COVID-19 infection may be associated with the ACE I/D polymorphism.
LIMITATIONS
CONCLUSIONS
Small sample size and single center.
CONFLICT OF INTEREST
BACKGROUND
None.
Identifiants
pubmed: 34085542
doi: 10.5144/0256-4947.2021.141
pmc: PMC8176375
doi:
Substances chimiques
Genetic Markers
0
ACE protein, human
EC 3.4.15.1
Peptidyl-Dipeptidase A
EC 3.4.15.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
141-146Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Circ Res. 2020 May 8;126(10):1456-1474
pubmed: 32264791
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Clin Chim Acta. 2020 Sep;508:110-114
pubmed: 32405080
Circ Res. 2000 Sep 1;87(5):E1-9
pubmed: 10969042
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620942129
pubmed: 32684101
Clin Chim Acta. 2020 Nov;510:455-458
pubmed: 32791137
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Br J Haematol. 2020 May;189(3):428-437
pubmed: 32297671
Int J Mol Sci. 2020 May 14;21(10):
pubmed: 32423094
J Infect. 2020 Dec;81(6):961-965
pubmed: 33197472
J Infect. 2020 Jun;80(6):656-665
pubmed: 32283155
BMC Geriatr. 2021 Jan 15;21(1):63
pubmed: 33451296
Med Hypotheses. 2020 Nov;144:110160
pubmed: 32795831
Infect Genet Evol. 2021 Mar;88:104682
pubmed: 33338639
Gene. 2020 Dec 15;762:145102
pubmed: 32882331
Clin Chim Acta. 2020 Jun;505:192-193
pubmed: 32220422
Am J Pathol. 2020 Oct;190(10):2013-2017
pubmed: 32735889